{
    "clinical_study": {
        "@rank": "97543", 
        "arm_group": {
            "arm_group_label": "Emotion Regulation Group Therapy (ERGT).", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary aim is to investigate the effectiveness of Emotion Regulation Group Therapy\n      (ERGT) for women who self-harm in ordinary psychiatric outpatient health care."
        }, 
        "brief_title": "ERGT for Women Engaging in NSSI - an Effectiveness Study", 
        "condition": [
            "Borderline Personality Disorder", 
            "Non-suicidal Self-injury (NSSI)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Borderline Personality Disorder", 
                "Personality Disorders", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NSSI a minimum of three times in the last six months\n\n          -  Meets at least three criteria for Borderline Personality Disorder according to\n             DSM-IV-TR\n\n          -  Contact with an other individual therapist, psychiatrist, \"case manager\" or equal\n\n        Exclusion Criteria:\n\n          -  Insertion/withdrawal of psychopharmacological substances within two months prior to\n             the treatment\n\n          -  Other acute primary axis I diagnosis (e.g. anorexia nervosa) that demand treatment in\n             first hand\n\n          -  Bipolar disorder I or primary psychosis\n\n          -  Current substance dependence (the last month)\n\n          -  Current life circumstances that would hinder the treatment (i.e. ongoing domestic\n             abuse)\n\n          -  Insufficient Swedish language skills\n\n          -  Cocurrent treatment with Mentalization based therapy (MBT) or Dialectical behavioral\n             therapy (DBT)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986257", 
            "org_study_id": "DNR 2013/1321-31/3"
        }, 
        "intervention": {
            "arm_group_label": "Emotion Regulation Group Therapy (ERGT).", 
            "intervention_name": "Emotion Regulation Group Therapy (ERGT).", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "contact": {
                "email": "johan.bjureberg@ki.se", 
                "last_name": "Johan Bjureberg, lic. Psychologist", 
                "phone": "+47 73 0917 112"
            }, 
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "113 64"
                }, 
                "name": "Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "Emotion Regulation Group Therapy (ERGT) for Women Engaging in Non-suicidal Self-Injury (NSSI) - an Effectiveness Study", 
        "overall_contact": {
            "email": "johan.bjureberg@ki.se", 
            "last_name": "Johan Bjureberg, lic. Psychologist", 
            "phone": "+46 73 0917112"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from Baseline in deliberate self-harm after 14 weeks and at 6- and 12 months after treatment has ended.", 
            "measure": "Frequency of non-suicidal self-injury as measured by Deliberate Self-Harm Inventory (DSHI)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (from inclusion to treatment start), (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986257"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Clara Hellner Gumpert", 
            "investigator_title": "Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from Baseline in self-destructive behaviors after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Borderline Symptom List Behavior supplement (BSL-supplement)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks), and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in difficulties with emotion regualtion after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Difficulties in Emotion Regulation Scale (DERS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in positive and negative affect after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Diary questionnaire (DQ)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in Borderline severity symptoms after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "The Borderline Evaluation of Severity over Time (BEST).", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in depression and anxiety after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "The Depression Anxiety Stress Scales (DASS)", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in interpersonal problems after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Inventory of Interpersonal Problems - Borderline Personality Disorder (IIP-BPD)", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in global functioning after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Sheehan Disability Scale (SDS)", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in societal costs after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, post-treatment (14 weeks) and six and twelve months follow-up."
            }, 
            {
                "description": "Change from Baseline in quality of life after 14 weeks and at 6- and 12 months after treatment has ended.", 
                "measure": "Euroqol-5D (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, post-treatment (14 weeks) and six and twelve months follow-up."
            }
        ], 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}